Status:
COMPLETED
A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
Lead Sponsor:
Wills Eye
Collaborating Sponsors:
Thomas Jefferson University
Conditions:
Retinoblastoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent yea...
Detailed Description
The management of retinoblastoma includes systemic chemotherapy (carboplatin, etoposide, and vincristine), thermotherapy, cryotherapy (freezing treatment), laser photocoagulation, plaque radiotherapy,...
Eligibility Criteria
Inclusion
- Advanced retinoblastoma in one or both eyes
- Recurrent retinoblastoma after failure of previous treatment
- No age limit (usually kids presenting with retinoblastoma present in the 1st two decades of life)
- Judged by principal investigator to be medically and physically able to undergo the procedure
Exclusion
- Recurrent retinoblastoma which is treatable with other conservative measures
- Invasive retinoblastoma (retinoblastoma that has grown locally outside of the eye, for example, into the bone around the eye)
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00857519
Start Date
January 1 2009
End Date
April 1 2014
Last Update
December 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Service, Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107